Efficacy of Jackfruit365™ Green Jackfruit Flour Fortified Diet on Pegfilgrastim to Prevent Chemotherapy-Induced Leukopenia, Irrespective of Tumor Type or Drugs Used—A Retrospective Study

Thomas Varughese ¹,* , James Joseph ² and Rejeesh Menon ³

¹ Department of Oncology, Renai Medicity Hospital, Palarivattom, Cochin, Kerala, Pin 682025, India
² God’s Own Food Solutions Pvt. Ltd., VII/219, Kaprassery, Nedumbassery, Kerala, Pin 683102, India; jamesjoseph@jackfruit365.com
³ Department of Medicine, Central Washington Hospital, Confluence Health, Wenatchee, Washington 98801, USA; Rejeesh.Menon@confluencehealth.org

* Correspondence: drthomasoncologist@gmail.com

Received: 30 December 2019; Accepted: 30 January 2020; Published: 2 February 2020

Abstract: Chemotherapy-Induced Leukopenia (CIL) is associated with increased mortality and economic burden on patients. This study was conducted to evaluate whether inclusion of green jackfruit flour in regular diet of those patients receiving chemotherapy, could prevent CIL. This was a retrospective study conducted among a group of patients undergoing chemotherapy for solid tumors at Renai Medicity Hospital, Palarivattom, Cochin, Kerala, India, since June 2018. The study group comprised of 50 consecutive subjects, who were supplemented with green jackfruit flour diet in their regular diet and further followed up prospectively. The control group was retrospective with 50 subjects prior to June 2018, with no diet supplements. Those who received less than three cycles were excluded from either arm. The mean age of the participants in study group and control group were 53.16 ± 11.06 and 56.96 ± 12.16 years respectively. In the study group, six patients out of 37, and 20 patients out of 50 in the control group, developed CIL. They received 38 and 105 vials of filgrastim respectively. After excluding those cycles in study group patients, where green jackfruit flour was not taken, the mean number of cycles in which CIL developed (p = 0.00) and number of vials of filgrastim taken per cycle (p = 0.00) were significantly different from control group and no patient in the study group developed CIL. Inclusion of green jackfruit flour as a dietary intervention prevents chemotherapy-induced leukopenia in patients undergoing chemotherapy along with pegfilgrastim.

Keywords: jackfruit; chemotherapy-induced leukopenia; chemotoxicity; pegfilgrastim; plant based compounds; natural compounds

1. Introduction

Dietary modification with more of vitamins, proteins and fibers for patients receiving chemotherapy has been in regular practice to aid better digestion and adequate nutrition. The intake of food substance as a dietary intervention to function as a hematopoietic growth factor preventing chemotherapy-induced leukopenia (CIL) is a novel concept in oncology [1]. Adjuvant, neo adjuvant or palliative chemotherapy is an essential part of solid tumor management. In addition to the destruction of the tumor cells, cytotoxic chemotherapy suppresses the hematopoietic system and results in impaired host protective mechanisms. Leukopenia is the most common side effect caused by chemotherapy, when white blood cells count drops below 4000. This often leading to limit doses of chemotherapy that can be tolerated [2]. It also causes delay in scheduling subsequent chemo cycles and associated with increased morbidity,
mortality, and increased treatment costs [3]. Leukopenia may result in febrile neutropenia (FN), which needs hospitalization for evaluation and administration of proper broad-spectrum antibiotics. Such complications usually result in reductions in dose or delay in treatment, which may compromise clinical outcomes [4–8]. Leukopenia is also associated with exacerbations of other adverse effects of chemotherapy [2], like diarrhea and mucosal ulcers, and respiratory complications like pneumonia, fatigue, electrolytic imbalance, etc. The predictors of CIL complications include advanced age, poor performance status, co-morbidities, and low baseline blood cell counts and high chemotherapy dose intensity [3].

The costs incurred in managing CIL include both direct medical costs and indirect costs following hospital admissions or intensive care that are borne by the patient. Numerous developments have occurred in the management of leukopenia, which include availability of hematopoietic growth factors and improvement in antibiotic therapy, yet this complication remains a central concern in the delivery of cancer chemotherapy [2]. Patients with febrile neutropenia may also develop sepsis, pneumonia or foci of infection, such as cellulitis. Approximately 10% of patients admitted with FN develop serious complications leading to death [9].

This can be mitigated by reducing chemotherapeutical doses or extending dosing intervals. However, these measures reduce the relative dose intensity (RDI) of chemotherapy, which has the disadvantage of reduced survival rates.

The prophylactic use of colony-stimulating factors (CSFs) like pegfilgrastim can reduce the risk, severity, and duration of both severe and febrile neutropenia [10–15]. Repeated admissions to manage leukopenia also escalate cost and reduce quality of life. Subcutaneous administration of pegfilgrastim after 24 h of chemotherapy is the current practice rather than daily administration of filgrastim to prevent leukopenia. However, previous randomized control studies show only 43.6% prevention in incidence of FN suggesting there is an unmet need to prevent CIL [16]. Hence, hemopoietic growth factors like filgrastim, are given once leukopenia sets in to prevent FN and eventual death.

*Artocarpus heterophyllus* Lam., which is commonly known as ‘jackfruit’ is a tropical climacteric fruit native to Western Ghats of India and common in Asia, Africa, and some regions in South America. Jackfruit is rich in nutrients including carbohydrates, proteins, vitamins, minerals, and phytochemicals. Several parts of jackfruit tree including fruits, leaves, and bark have been extensively used in traditional medicine due to its anticarcinogenic, antimicrobial, antifungal, anti-inflammatory, wound healing, and hypoglycemic effects [17]. The tradition of consuming mature green jackfruit as a meal has emerged as an effective alternate to rice to control blood sugar levels due to its soluble fiber, pectin, and lower glycemic load [18]. Researchers have reported that jackfruit seed extract has anti-inflammatory properties indicating its anti-cancer properties [19].

Studies [20–22] have shown that jackfruit contains many classes of phytochemicals such as carotenoids, which have beneficial effects on several chronic degenerative diseases and cancers. Phytonutrients such as lignans, isoflavones, and saponins in jackfruit contribute to its anticancer property. They may aid in preventing carcinogens by changing milieu and fight against stomach ulcers [23]. The results of a study carried out by Ruiz-Montanez et al. [24] suggested that jackfruit possesses compounds with chemo protective properties to reduce the mutagenicity of aflatoxin B1 (AFB1) and proliferation of cancer cells. In addition to these anticancer effects, researchers have reported that dietary pectin, present in green jackfruit flour, increases survival of bone marrow cells and intestinal crypt stem cells during chemo and radiotherapy. This study was conducted to test whether inclusion of green jackfruit flour in the diet of patients undergoing chemotherapy reduces development of leukopenia.

2. Materials and Methods

This was a retrospective cohort study conducted among patients undergoing chemotherapy for solid tumors at the Department of Oncology, Renai Medicity Hospital, Palarivattom, Cochin, Kerala, India.
The study group comprised of 50 consecutive subjects, who followed the inclusion of green jackfruit flour in their regular diet (referred as JFD) and followed up. The control group comprised of 50 subjects with no specific diet supplements and followed their regular diet. Regular diet of patients in both groups include vegetarian and non-vegetarian dishes with importance to fish accompanied with rice meal or meals prepared with rice or wheat flour. The two groups of patients matched with regards to gender, age, types of solid tumors, types of chemotherapy drugs used, pegylated filgrastim used and chemotherapy protocols followed in the oncology clinic.

The solid tumors included cancers of the breasts, lungs, buccal mucosa, tongue, pharynx, cancers of head and neck, stomach, esophagus, gastro esophageal junction, colon, rectum, pancreas, cancers of gastro intestinal system, bladder, ovaries, uterus, cervix, and soft tissue sarcomas (supplementary data Table S1). The chemotherapeutic drugs used include, taxanes, anthracyclines, holoxan, platinums, targeted chemotherapeutic drugs like herceptin, bevacizumab, nimotuzumab (supplementary data Table S2). Chemotherapy was given in the neo adjuvant, adjuvant or palliative indications if performance status was acceptable. Those who received less than three cycles were excluded from either arm.

The study was approved on September 6th, 2019 by the Renai Medicity Hospital institutional ethics committee (Reg. No. ECR/1113/Inst/KL/2018. Ref No.HR/RIMS/158/2019).

2.1. Intervention

Apart from the regular diet patients in the study arm were advised to include 30 g of green jackfruit flour to rice or wheat flour they used to prepare meals in equal divided doses with breakfast and dinner, without changing any other elements of day today food habits. Jackfruit365™ Green Jackfruit Flour is a patent pending formulation of dehydrated mature green jackfruit fruits fortified with protein and pectin from other parts of jackfruit. 30 g of green jackfruit flour is obtained from 150 g of fresh jackfruit traditionally used to prepare one portion of jackfruit meal for one person and contains 108 Kcal of energy, 20 g of net carbohydrates, 1 g of sugar, 4 g fiber of which 1 g is soluble fiber pectin, 0.4 g of fat, 2 g of protein with 17 types of amino acids, and 0.4 g potassium.

Study group patients given coupons to buy green jackfruit flour packs from the local grocery shops and records were maintained. Patients were advised to take 30 g of green jackfruit flour per day along with staple food from first day of chemotherapy through the last day of each cycle of 21 days, till the completion of the course. Blood examination for Hb, WBC count and platelet counts were done on 5th, 7th, 9th, and 12th day as per standard protocol to watch out for any signs of leukopenia. Patients presented with WBC count of less than 4000 got daily doses of filgrastim till their WBC count reached above 4000. Data of filgrastim use was maintained in hospital patient records and in the pharmacy. No extra invasive or non-invasive tests or procedures were conducted on the patient for the study.

In the study arm addition of Jackfruit flour to the diet was the patient’s choice however the benefits of the JFD were explained to all. The final pathology report was critically evaluated in all the subjects who received neo adjuvant chemotherapy to assess any adverse or beneficial effects of JFD on the tumor impacting chemo response.

Adoption for JFD was high as it was part of the traditional diet with no known adverse effects. Those who refused JFD initially, in the prospective group, were studied separately.

2.2. Statistical Analysis

Data were checked for completeness and consistency and entered in SPSS version 20 software (IBM, Armonk, NY, US). Descriptive statistics like percentages and mean were used. Analysis was done using ANOVA test for comparison between study and control group. \( p \) value less than 0.05 was considered statistically significant.
3. Results

After excluding patients who received less than three cycles of chemotherapy, analysis was done for a total of 87 patients with 37 patients in study group and 50 patients in control group. Table 1 shows that about 70.3% of the participants were females in study group and 74.0% of the participants were females in control group. About 62.2% and 50% of the participants received neoadjuvant chemotherapy in study group and control group respectively. The mean age of participants in the study group and the control group were 53.16 ± 11.06 years and 56.96 ± 12.16 years respectively (Table 1).

| Variable       | Category  | Study       | Control     |
|----------------|-----------|-------------|-------------|
| Gender         | Male      | 11 (29.7%)  | 13 (26.0%)  |
|                | Female    | 26 (70.3%)  | 37 (74.0%)  |
| Adjuvant       |           | 12 (32.4%)  | 21 (42.0%)  |
| Therapy given  | Neo adjuvant | 23 (62.2%)  | 25 (50.0%)  |
|                | Palliative | 2 (5.4%)    | 4 (8.0%)    |
| Age (Mean ± SD)|           | 53.16 ± 11.06 | 56.96 ± 12.16 |

The participants in control group developed leukopenia in 37 out of 263 cycles of chemotherapy received and 14 out of 232 in the study group. We found six patients in the study group and 20 patients in the control group developed leukopenia respectively. Twenty patients in the control group required 105 vials of filgrastim whereas only six patients in the study group required a total of 38 vials of filgrastim (Table 2).

| Study Group | Control Group |
|-------------|---------------|
| Total number of cycles of chemotherapy given | 232 | 263 |
| Number of cycles in which leukopenia was present | 14 | 37 |
| Number of vials of filgrastim taken | 38 | 105 |
| Number of patients for whom leukopenia occurred | 6 | 20 |

(INCLUDING THOSE CYCLES FROM STUDY GROUP PATIENTS WHERE JACKFRUIT FLOUR DIET (JFD) WAS NOT TAKEN).

After excluding those cycles in study group patients, where JFD was not taken, none of the patients in study group developed leukopenia in any cycle out of the 211 cycles of chemotherapy (Table 3).

| Study Group | Control Group |
|-------------|---------------|
| Total number of cycles of chemotherapy given | 211 | 263 |
| Number of cycles in which leukopenia was present | 0 | 37 |
| Number of vials of filgrastim taken | 0 | 105 |
| Number of patients for whom leukopenia occurred | 0 | 20 |

(AFTER EXCLUDING THOSE CYCLES FROM STUDY GROUP PATIENTS WHERE JFD WAS NOT TAKEN).

There was no significant difference in the mean number of cycles of chemotherapy received by patients between the two groups, study group (6.27 ± 2.58) vs control group (5.26 ± 2.52). Significant
difference was not found ($p = 0.15$) between the mean number of vials of filgrastim taken per patient in study group (1.02 ± 3.25) and control group (2.10 ± 3.59) respectively (Table 4).

Table 4. Difference between parameters in study and control group.

| Parameter                                | Study Group (mean ± SD) | Control Group (mean ± SD) | $p$-Value |
|------------------------------------------|-------------------------|---------------------------|-----------|
| Number of cycles of chemotherapy per patient | 6.27 ± 2.58             | 5.26 ± 2.52               | 0.07      |
| Number of vials of filgrastim taken per patient | 1.02 ± 3.25             | 2.10 ± 3.59               | 0.15      |

After excluding the cycles in study group in which JFD was not taken, the mean number of cycles of chemotherapy received by patients in the study group was 5.70 ± 2.73 and it was not significantly different ($p = 0.44$) from the patients in the control group (5.26 ± 2.52). In addition, mean number of cycles in which leukopenia occurred in the study group (0.00 ± 0.00, $p = 0.00$) and mean number of vials of filgrastim taken per patient in the study group (0.00 ± 0.00, $p = 0.00$) were significantly lesser as compared to the control group (Table 5).

Table 5. Difference between parameters in study and control group.

| Parameter                                | Study Group (Mean ± SD) | Control Group (Mean ± SD) | $p$-Value |
|------------------------------------------|-------------------------|---------------------------|-----------|
| Number of cycles of chemotherapy per patient | 5.70 ± 2.73             | 5.26 ± 2.52               | 0.44      |
| Number of cycles in which leukopenia was present per patient | 0                       | 0.74 ± 1.05               | 0.00      |
| Number of vials of filgrastim taken per patient | 0                       | 2.10 ± 3.59               | 0.00      |

(After excluding those cycles from study group patients where JFD was not taken).

In the study group, two patients could not take any oral food due to their cancer and could not take JFD in any cycles. Four patients switched to JFD only after they experienced leukopenia without JFD. Patients in study group who followed JFD in all cycles did not experience leukopenia. Green jackfruit flour supplement during chemotherapy, after prophylactic pegfilgrastim, was associated with complete prevention of leukopenia, enhancing the clinical utility of pegfilgrastim (Figure 1).

Figure 1. Effect of JFD in the prevention of Leukopenia; * Including six patients who could not take JFD in all cycles.

This was also shown in Figure 2 where monthly average sales of filgrastim from hospital pharmacy reduced from 14.87 vials to just 2.66 vials after the introduction of JFD and it was only required for patients who didn’t take JFD.
with a multivitamin or vitamin E. There is growing evidence that these dietary supplements can mimic, when widely used. The quality of life and psychological satisfaction when leukopenia and neutropenia prevent cancer could also prevent the leukopenia caused by chemotherapy.

Peel serve as natural antioxidants in food production [29,30]. Antioxidants present in jackfruit which pectin includes galacturonic acid, glucose, arabinose, galactose, and rhamnose. Pectins from jackfruit protects the intestinal crypt stem cells during chemotherapy [25–28]. Pectin from jackfruit peel could prevent e...in the study arm suggesting absence of adverse response of JFD to the actions of the drugs on the cancer.

4. Discussion

Dietary intervention to prevent leukopenia and neutropenia, for those who undergo chemotherapy is reported for the first time. Jackfruit is a tropical fruit available in several countries. The anti-diabetic effect of green jackfruit is well established. The treatment cost reduced by avoiding administration of hematopoietic growth factor, antibiotics, and repeated hospital admissions, could be phenomenal when widely used. The quality of life and psychological satisfaction when leukopenia and neutropenia are reduced during chemotherapy, adds value to this novel dietary intervention. The leukopenia prevention effect of green jackfruit flour is proved in this study by the fact that the mean number of cycles in which leukopenia developed and the number of vials of filgrastim required is significantly lower in the patients who received green jackfruit flour diet. The mechanism of leukopenia prevention effect of jackfruit can be attributed to the pectin component present in green jackfruit flour which protects the intestinal crypt stem cells during chemotherapy [33,34]. Presence of these vitamins and beneficial phytochemicals such as carotenoids, lignans, isoflavones, and saponins in green jackfruit flour need to be investigated.

Figure 2. Average monthly sales quantity in vials for filgrastim from hospital pharmacy.

Around fifty percent of the subjects in either arm received neoadjuvant chemotherapy. Pathology reports showed that response to chemotherapy was better with more complete pathological responses in the study arm suggesting absence of adverse response of JFD to the actions of the drugs on the cancer.

The possible action of bone marrow stimulation by amino acids present in jackfruit similar to filgrastim need to be investigated [31]. This action could be intensified by increased nutrient absorption with green jackfruit flour diet. Previous studies shown that amino acids provide better nutrition in patients undergoing chemotherapy. Most of the normal nutrient absorption happens at the small intestinal villus surface which is damaged after chemotherapy and alters the normal absorptive mechanism. In these conditions amino acids shown to be better nutrients and reduces the gastrointestinal syndrome following chemotherapy [32]. The same mechanism is plausible in case of green jackfruit flour as it contains significant amount of potassium and amino acids which in turn can reduce the gastrointestinal side effects of chemotherapy (supplementary data Table S3). The decrease in neutrophil count caused by chemotherapy is ameliorated by dietary supplementation with a multivitamin or vitamin E. There is growing evidence that these dietary supplements can mimic, intensify, or attenuate the effects of chemotherapeutic agents [33,34]. Presence of these vitamins and beneficial phytochemicals such as carotenoids, lignans, isoflavones, and saponins in green jackfruit flour need to be investigated.

The strength of the study is that this is a novel dietary intervention study with a local plant-based food where the patients in the study group are followed up prospectively in a real life clinical setting.
There are two limitations for the study. For study group, no extra data from invasive or non-invasive procedures or tests could be collected and for control group, data were collected retrospectively and limited to available hospital patient records.

Irrespective of the type of tumor or the drugs and regimens used, the end result of leukopenia prevention was identical. There are several reports and meta-analysis examining the impact of Capecitabine in combination with standard neoadjuvant and adjuvant chemotherapy regimens in early breast cancer. These suggest improved outcomes in survival in breast cancer patients. All the patients with poor prognostic variables like triple negative, Er negative, HER2 positive tumors, those with axillary node positivity, high Ki67, vascular invasions, lymphatic invasions, perineural invasions and perinodal extensions showed better survival [35].

The biggest limiting factors are the hand foot syndromes and diarrhea for those who are on oral Capecitabine in pharmacological doses. Therefore, dose reductions or avoidance of the drug will be usually advised, which obviously negates the final outcome. In the study group and control group oral Capecitabine was part of the protocol. Among those who are on JFD, no patient experienced these complications, denoting the fact JFD can even improve survival in those high-risk groups.

5. Conclusions

This study concludes that addition of green jackfruit flour as a dietary intervention prevents Chemotherapy Induced Leukopenia (CIL). The impact on global scenario will be recruitment of more patients, who due to toxicity, fail to complete ideal treatments as well as those who refuse chemotherapy due to the fear of developing leukopenia, as experienced by peers.

The combined effect of green jackfruit flour in combination with pegfilgrastim, resulting in complete avoidance of leukopenia is a breakthrough in the field of oncology. This is reported for the first time. Since the scientific community is on the lookout for more natural and plant-based products to treat health related issues on account of unexpected adverse reactions from synthetic agents, the current observational study on green jackfruit flour opens new frontiers for interventions.

Complete avoidance of leukopenia, greatly enhances the quality of life of treating doctor and staff as well, since they need not waste precious hours for treating complications of chemotherapy. Advanced researches on more dose intensive chemotherapy or frequent scheduling also could be done, which may improve the patient’s compliance, outcome and physician’s esteem.

Further prospective multicenter randomized controlled trials with adequate sample and additional physical and hematological data to establish evidence of leukopenia prevention effect of green jackfruit flour can be studied in different disease subgroups, with different regimens both in adult and pediatric category. The cost effectiveness in preventing leukopenia when translated into money saved globally, will be in billions.

Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/2/218/s1. Table S1: Baseline Table Which Include Tumor Type between Study and Control Group Patients, Table S2: Baseline Table of Drug Type between Study and Control Group Patients and Table S3: Analytical Report for Amino Acid Profile and Potassium

Author Contributions: J.J. prepared the manuscript, T.V. formulated study design, collected data, and edited manuscript, and R.M. helped to prepare manuscript, review, and analyze the data. All authors have read and agreed to the published version of the manuscript.

Funding: God’s Own Food Solutions Pvt. Ltd. for supply of green jackfruit flour and research assistants’ fees for assisting with data collection, analysis and report preparation.

Acknowledgments: We would like to thank Anita Paul for data collection and preparation of tables and staff at Renai Medicity for administrative and technical support in data collection.

Conflicts of Interest: J.J. is the inventor of Jackfruit365™ Green Jackfruit Flour with a pending patent and is the founder of Jackfruit365.com and managing director of God’s Own Food Solutions Pvt. Ltd. which along with its subsidiaries manufacture and market the product. T.V. and R.M. declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References

1. Varughese, T.; Joseph, J. Can green jackfruit flour as a nutritional supplement replace haemopoietic growth factor? *J. Nutr. Food. Sci.* 2019, 9, 29–30. [CrossRef]

2. Crawford, J.; Dale, D.C.; Lyman, G.H. Chemotherapy induced neutropenia: risks, consequences, new directions for its management. *Cancer* 2004, 100, 228–237. [CrossRef] [PubMed]

3. Lyman, G.H.; Lyman, C.H.; Agboola, O. Risk Models for Predicting Chemotherapy-Induced Neutropenia. *Oncologist* 2005, 10, 427–437. [CrossRef] [PubMed]

4. Ozer, H.; Armitage, J.O.; Bennett, C.L. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. *J. Clin. Oncol.* 2000, 18, 3558–3585. [CrossRef]

5. Rolston, K.V. New trends in patient management: risk-based therapy for febrile patients with neutropenia. *Clin. Infect. Dis.* 1999, 29, 515–521. [CrossRef]

6. Bonadonna, G.; Valagussa, P.; Moliterni, A.; Zambetti, M.; Brambilla, C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: the results of 20 years of follow-up. *N. Engl. J. Med.* 1995, 332, 901–906. [CrossRef]

7. Budman, D.R.; Berry, D.A.; Cirrincione, C.T. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. *J. Natl. Cancer. Inst.* 1998, 90, 1205–1211. [CrossRef]

8. Kwak, L.W.; Halpern, J.; Olshen, R.A. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. *J. Clin. Oncol.* 1990, 8, 963–977. [CrossRef]

9. Kuderer, N.M.; Dale, D.C.; Crawford, J.; Cosler, L.E.; Lyman, G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. *Cancer* 2006, 106, 2258–2266. [CrossRef]

10. Crawford, J.; Ozer, H.; Stoller, R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. *N. Engl. J. Med.* 1991, 325, 164–170. [CrossRef]

11. Pettengell, R.; Gurney, H.; Radford, J.A. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. *Blood* 1992, 80, 1430–1436. [CrossRef] [PubMed]

12. Holmes, F.A.; O’Shaughnessy, J.A.; Vukelja, S. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. *J. Clin. Oncol.* 2002, 20, 727–731. [CrossRef] [PubMed]

13. Green, M.D.; Koelbl, H.; Baselga, J.A. Randomized double blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. *Ann. Oncol.* 2003, 14, 29–35. [CrossRef] [PubMed]

14. Dale, D.C. Colony-stimulating factors for the management of neutropenia in cancer patients. *Drugs* 2002, 62, 1–15. [CrossRef] [PubMed]

15. Kubo, K.; Miyazaki, Y.; Murayama, T.; Shimazaki, R.; Usui, N.; Urabe, A.; Hotta, T.; Tamura, K. A randomized, double-blind trial of pegfilgrastim versus daily filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. *Br. J. Haematol.* 2016, 174, 563–570. [CrossRef]

16. Joseph, J. Nutritional, Glycemic and Ecological Assessment of Green Jackfruit for Diabetes in Kerala. *Int. J. Diab.* 2019, 14–18.

17. Ranasinghe, R.A.S.N.; Maduwanthi, S.D.T.; Marapana, R.A.U.J. A Nutritional and Health Benefits of Jackfruit (*Artocarpus heterophyllus* Lam.): A Review. *Int. J Food. Sci.* 2019, 6, 1–12. [CrossRef]

18. Yao, X.; Wu, D.; Dong, N.; Ouyang, P.; Pu, J.; Hu, Q.; Wang, J.; Lu, W.; Huang, J. Moracin C, A Phenolic Compound Isolated from *Artocarpus heterophyllus*, Suppresses Lipopolysaccharide-Activated Inflammatory Responses in Murine Raw264.7 Macrophages. *Int. J. Mol. Sci.* 2016, 17. [CrossRef]

19. Ong, B.T.; Nazimah, S.A.H.; Osman, A. Chemical and flavour changes in jackfruit (*Artocarpus heterophyllus* Lam.) cultivar J3 during ripening. *Postharvest Biol. Technol.* 2006, 40, 279–286. [CrossRef]
21. Arung, E.T.; Shimizu, K.; Kondo, R. Structure-activity relationship of prenyl-substituted polyphenols from *Artocarpus heterophyllus* as inhibitors of melanin biosynthesis in cultured melanoma cells. *Chem. Biodivers.* 2007, 4, 2166–2171. [CrossRef] [PubMed]

22. Chandrika, U.G.; Jansz, E.R.; Warnasuriya, N.D. Analysis of carotenoids in ripe jackfruit (*Artocarpus heterophyllus*) kernel and study of their bioconversion in rats. *J. Sci. Food Agric.* 2004, 85, 186–190. [CrossRef]

23. Baliga, M.S.; Shivashankara, A.R.; Hanadika, R.; Dsouza, J.; Bhat, H.P. Phytochemistry, nutritional and pharmacological properties of *Artocarpus heterophyllus* Lam. (jackfruit): A review. *Food Res. Int.* 2011, 44, 1800–1811. [CrossRef]

24. Ruiz-Montanez, G.; Burgos-Hernandez, A.; Calderón-Santoyo, M. Screening antimutagenic and anti proliferative properties of extracts isolated from Jackfruit pulp (*Artocarpus heterophyllus* Lam). *Food Chem.* 2015, 175, 409–416. [CrossRef]

25. Sureban, S.M.; May, R.; Qu, D.; Chandrakesan, P.; Weygant, N.; Ali, N.; Lightfoot, S.A.; Ding, K.; Umar, S.; Schlosser, M.J.; Houchen, C.W. Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury. *PLoS One* 2015, 10. [CrossRef] [PubMed]

26. Guess, B.W.; Scholz, M.C.; Strum, S.B.; Lam, R.Y.; Johnson, H.J.; Jennrich, R.I. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. *Prostate Cancer Prostatic Dis.* 2003, 6, 301–304. [CrossRef] [PubMed]

27. Gunning, A.P.; Bongaerts, P.V.; Morris, V.J. Recognition of galactan components of pectin by galectin-3. *FASEB J.* 2009, 23, 409–416. [CrossRef]

28. Leclere, L.; Cutsem, P.V.; Michiels, C. Anti-cancer activities of pH- or heat-modified pectin. *Front. Pharmacol.* 2013, 4. [CrossRef]

29. Xu, S.-Y.; Liu, J.-P.; Huang, X.; Du, L.-P.; Shi, F.-L.; Dong, R.; Huang, X.-T.; Zheng, K.; Liu, Y.; Cheong, K.-L. Ultrasonic-microwave assisted extraction, characterization and biological activity of pectin from jackfruit peel. *LWT Food Sci. Technol.* 2018, 90, 577–582. [CrossRef]

30. Minzanova, S.T.; Mironov, V.F.; Arkipova, D.M.; Khabibullina, A.V.; Mironova, L.G.; Zakirova, Y.M.; Milyukov, V.A. Biological activity and pharmacological application of pectic polysaccharides: A review. *Polymers* 2018, 10. [CrossRef]

31. Izzo, A.A.; Ernst, E. Interactions between herbal medicines and prescribed drugs. a systematic review. *Drugs* 2001, 61, 2163–2175. [CrossRef] [PubMed]

32. Yin, L.; Vijaygopal, P.; Menon, R.; Vaught, L.A.; Zhang, M.; Zhang, L.; Okunieff, P.; Vidyasagar, S. An Amino Acid Mixture Mitigates Radiation-induced Gastrointestinal Toxicity. *Health Phys.* 2014, 106, 734–744. [CrossRef] [PubMed]

33. Fugh-Berman, A. Herb-drug interactions. *Lancet* 2000, 355, 134–138. [CrossRef]

34. Branda, R.F.; Naud, S.J.; Brooks, E.M.; Chen, Z.; Muss, H. Effect of vitamin B12, folate and dietary supplements on breast carcinoma chemotherapy-induced mucositis and neutropenia. *Cancer* 2004, 101, 1058–1064. [CrossRef]

35. Natori, A.; Ethier, J.L.; Amir, E.; Cescon, D.W. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. *Eur J. Cancer.* 2017, 77, 40–47. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).